Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors and Bispecific Antibody Checkpoint Inhibitor Platform BiCKI® and BiCKI®-IL-7 -What is the next step for...

Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors and Bispecific Antibody Checkpoint Inhibitor Platform BiCKI® and BiCKI®-IL-7 -What is the next step for...

User Photo
Cancer-News

1 month
7 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Nicolas Poirier, Ph.D. - OSE Immunotherapeutics - discusses Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology and New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy - What is the next step for this research?
Up Next Autoplay